更新卡博普拉丁过敏性协议:两个案例研究
Kimberly Ann Stout1, Briana Miller2
1Kimberly Ann Stout.
Clinical journal of oncology nursing
|March 17, 2025
概括
一个新的碳波拉丁脱敏协议改善了患者对妇科癌症治疗的耐受性. 这一更新的协议是安全的,有效的,并降低了医疗保健成本.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
背景情况:
- 碳白金是治疗妇科癌症的关键化疗剂.
- 再次暴露于卡博普拉丁可以引发过敏反应,给患者带来风险.
- 现有的碳金脱敏方案缺乏标准化.
研究的目的:
- 更新一个现有的碳烯脱敏化协议.
- 为了使协议与当前的最佳实践保持一致.
- 通过减少劳动力和缩短住院时间来实现成本节约.
主要方法:
- 实施修订后的四袋,四小时的碳烯脱敏化方案.
- 五个已完成的无敏化程序的回顾性审查.
- 使用常用术语标准对不良事件进行安全性和耐受性的评估.
主要成果:
- 对两名患者进行了五次成功的脱敏治疗.
- 每次消毒都节省了药房成本200美元 (108美元供应,92美元劳动力).
- 护理费用节省大约为每次无敏化400美元.
结论:
- 更新的卡博普拉丁脱敏方案是安全的,并且耐受性很好.
- 该协议为医疗机构提供了显著的成本节约.
- 碳金脱敏的标准化有助于改善患者管理.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.1K
相关概念视频
02:49Cancer Therapies
8.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
01:30Drug Toxicity: Allergic Reactions
223
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
223